Publication search results

Found 481 Results
Page 1 of 49

Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States


Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States Authors: Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B and Mamtani R. Publication type: Journal article Publication name: Clinical Genitourinary Cancer Citation: Hale […]

Uncategorised

24th July 2020


Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: a pharmaco-economic assessment


Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: a pharmaco-economic assessment Authors: Uyl-de Groot CA, Ramsden R, Lee D, Boersma J, Zweegman S and Dhanasiri S. Publication type: Journal article Publication name: European Journal of Haematology Citation: Uyl-de Groot CA, Ramsden R, Lee D, Boersma J, Zweegman S and […]

Uncategorised

23rd July 2020


Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection


Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection Authors: Bullement A, Willis A, Amin A, Schlichting M, Hatswell AJ and Bharmal M. Publication type: Journal article Publication name: BMC Medical Research Methodology Citation: Bullement A, Willis A, Amin A, Schlichting M, Hatswell AJ and Bharmal M. […]

Uncategorised

6th May 2020


Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma


Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma Authors: Hemstock M, Amadi A, Kupas K, Roskell N, Kotapati S, Gooden K, Middleton MR and Schadendorf D Publication type: Journal article Publication name: Eur. J. Cancer Citation: Hemstock M, Amadi A, Kupas K, Roskell N, Kotapati S, Gooden K, Middleton MR […]

Uncategorised

4th May 2020


The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer


The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer Authors: Gregory J, Dyer M, Hoyle C, Mann H and Hatswell AJ. Publication type: Journal article Publication name: Health Economics Review Citation: Gregory J, Dyer M, Hoyle C, Mann H and Hatswell AJ. The validation of […]

Uncategorised

21st April 2020


Investigating non-protocol-driven hospitalizations to assess darolutamide tolerability in patients with non-metastatic castration-resistant prostate cancer


Investigating non-protocol-driven hospitalizations to assess darolutamide tolerability in patients with non-metastatic castration-resistant prostate cancer Authors: Upton A, Roskell N, Keenan C, Chen S, Jackson L and Shore N. Publication type: Conference Proceedings – Poster Publication Name: Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2020 Citation: Upton A, Roskell N, Keenan C, Chen S, Jackson […]

Uncategorised

20th April 2020


R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study


R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study Authors: Hart R, Burns D, Ramaekers B, Ren S, Gladwell D, Sullivan W, Davison N, Saunders O, Sly I, Cain T and Lee D. Publication type: Journal article Publication name: Pharmacoeconomics Citation: Hart R, Burns D, Ramaekers B, Ren S, Gladwell D, […]

Uncategorised

31st March 2020


The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States


The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States Authors: Slater RL, Lai Y, Zhong Y, Li H, Meng Y, Homet Moreno B, Godwin JL, Frenkl T, Sonpavde GP and Mamtani R Publication type: Journal article Publication name: Journal of Medical Economics Citation: Slater […]

Uncategorised

15th March 2020


“Stick or Twist?” Negotiating Price and Data in an Era of Conditional Approval


“Stick or Twist?” Negotiating Price and Data in an Era of Conditional Approval Authors: Gladwell D, Bullement A, Cowell W, Patterson K and Strong M Publication type: Journal article Publication name: Value in Health Citation: Gladwell D, Bullement A, Cowell W, Patterson K and Strong M. “Stick or Twist?” Negotiating Price and Data in an […]

Uncategorised

26th February 2020


A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity


A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity Authors: Grant T, Burns D, Kiff C and Lee D Publication type: Journal article Publication name: Pharmacoeconomics Citation: Grant T, Burns D, Kiff C and Lee D. A Case Study Examining the Usefulness of Cure Modelling for […]

Uncategorised

18th December 2019


Page 1 of 49
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies